Legend Biotech Company Analysis & Research
Legend Biotech is the largest standalone cell therapy company with more than 2,900 employees, specializing in CAR-T cell therapy with CARVYKTI as its lead asset, a one-time treatment for relapsed or refractory multiple myeloma developed and marketed with Johnson & Johnson collaborator. CARVYKTI has treated over 10,000 patients with global availability expanded to over 279 sites across 14 markets. The company is at an inflection point with commercial and profitability milestones approaching in 2026.
Legend Biotech expects to achieve company-wide operating profit in 2026, supported by massive expansion of its Raritan manufacturing facility. The company develops and commercializes advanced oncology treatments primarily through its Johnson & Johnson collaboration, while diversifying its pipeline into allogeneic and in vivo therapies. CARVYKTI has cemented its status as the undisputed leader in multiple myeloma CAR-T cell therapy with record-breaking performance.
Company Overview
Founded: 2014. Headquarters: Somerset, New Jersey. Revenue: $524M (Q3 2025 CARVYKTI sales). Employees: 2,900+. Ticker: LEGN (NASDAQ).
Industry
Biotechnology / Cell & Gene Therapy / CAR-T Cell Therapy
Cyborg Score: 8/10 — Strong
Market-leading CAR-T franchise achieving profitability at scale with differentiated clinical data and manufacturing capacity advantage.
The expanded Raritan facility is the largest cell therapy manufacturing facility in the U.S., capable of treating 10,000 patients annually. Triple-class-exposed patients achieved median progression-free survival of 50.4 months after single infusion, and the company targets 2026 profitability with strong cash position.
Key Strategic Insights for Legend Biotech
- Q3 2025 results highlighted $524M CARVYKTI net trade sales and approximately $1.0B in cash and time deposits
- Phase 3 CARTITUDE-6 trial enrollment for newly diagnosed, transplant-eligible patients completed in August 2025, potentially opening frontline multiple myeloma market
- Management dosed first patient using in vivo platform for dual CD20/CD19-targeted therapy with initial human data expected in second half of 2026
- Recent positive clinical updates met with muted market reactions, suggesting potential valuation gap between clinical achievement and stock performance
Recent Developments
- (February 2026) Legend Biotech to present CARVYKTI data at Tandem Meetings with focus on earlier-line use and safety
- (January 2026) Company outlined 2026 priorities including profitability targets and continued CARVYKTI global expansion at J.P. Morgan Healthcare Conference
- (December 2025) ASH 2025 presentations highlighted 50.4-month median PFS data and first-in-human results from novel CAR-T platform
Competitors & Competitive Landscape
- Miltenyi Biotech — CAR-T cell therapy for mantle cell lymphoma
- Kite Pharma (Gilead) — CAR-T cell therapy for lymphoid malignancies
- Janssen Biotech (Johnson & Johnson) — CAR-T cell therapy for multiple myeloma
Legend is maintaining leadership in cell therapy while diversifying into allogeneic and in vivo therapies as cell therapy moves beyond traditional autologous manufacturing. CARVYKTI competes with other CAR-T therapies in multiple myeloma, while the company is also advancing pipeline candidates targeting NHL, leukemia, and solid tumors with differentiated clinical efficacy.
More Company Research
Transaction Capital Limited (Nutun Limited) Grange Resources Limited Qatar Islamic Insurance Group Q.P.S.C. JCR Pharmaceuticals Co., Ltd. Placoplatre SA MillerKnoll, Inc. Intershop Holding AG Rathbones Group Plc PT Elang Mahkota Teknologi Tbk Vaxcyte, Inc. Schroders plc Samsung Heavy Industries Co., Ltd. Copart, Inc. Dish TV India Limited WiMi Hologram Cloud Inc.Full Company Research Reports
Looking for a more in-depth analysis of Legend Biotech? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.